Marketing application for Adalimumab

Adalimumab (Adalimumab) was originally launched in the United States by Abbvie (Abbvie) and was launched in Approved bythe U.S. Food and Drug Administration (FDA) in 2002, the drug is commonly known asHumira. It is produced by recombinant DNA technology using a mammalian cell expression system. This medication is available as a prefilled syringe and a convenient pen for subcutaneous self-administration. Adalimumab was marketed in the European Union through the European Medicines Agency (EMA) in 2003 and has proven to be effective in reducing symptoms in patients with inflammation. In 2019, it was approved by the National Medical Products Administration and was launched for sale in China. It can also be called Humira.